Pentosan polysulfate - Paradigm Biopharmaceuticals

Drug Profile

Pentosan polysulfate - Paradigm Biopharmaceuticals

Alternative Names: Pentosan polysulfate sodium; PPS - Paradigm Biopharmaceuticals; Rhinosul

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Paradigm Pharmaceuticals
  • Class Anti-inflammatories; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis
  • Phase I Allergic rhinitis

Most Recent Events

  • 14 Nov 2016 Phase-II clinical trials in Seasonal allergic rhinitis in Sweden (Intranasal) (EudraCT2016-003341-28)
  • 20 Jun 2016 Phase-I clinical trials in Allergic rhinitis (In volunteers) in Australia (Intranasal) (ACTRN12616000676415)
  • 01 Jun 2016 Preclinical trials in Allergic rhinitis in Australia (Intranasal) (ACTRN12616000676415p) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top